Glioblastoma, IDH-Wildtype — Trials

Glioblastoma, IDH-Wildtype — Trials · CancerIndex

Clinical trials

Registered studies

303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 42
Ph III recruiting: 3
Growth YoY: —
Industry share: 12%
Top sponsor: Mayo Clinic
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (64)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05759195	Biomolecular Analysis for Predicting Response to Regorafenib(RegoRec)	completed	N/A	53	Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER	1	Mar 13, 2025	clinicaltrials
NCT01165671	Carbon Ion Radiotherapy for Primary Glioblastoma(CLEOPATRA)	completed	N/A	100	University Hospital HeidelbergOTHER	1	Apr 3, 2020